Diabetes Research and Clinical Practice
Volume 95, Issue 1 , Pages 10-18 , January 2012

Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: A multicenter, observational, primary care study conducted in Finland

  • Jyrki K. Mäkelä

      Affiliations

    • Mehiläinen Lahti, Sibeliuksenkatu 6C, Lahti, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +358 44 077 1654; fax: +358 3 8255 290.
    • ,
  • Christine Schmüser

      Affiliations

    • Pohjois-Pori Health Centre, Pori, Finland
    • ,
  • Kari Askonen

      Affiliations

    • Ylitornio Health Centre, Ylitornio, Finland
    • ,
  • Tero Saukkonen

      Affiliations

    • Clinical, Medical & Regulatory Department, Novo Nordisk Farma Oy, Espoo, Finland

Received 2 February 2011 ,Revised 25 May 2011 ,Accepted 6 June 2011.

  • Image Result

    Patient flow. (a) One patient did not provide information on prior therapy so was not counted here, but was included in the overall efficacy and safety populations (total recruited: n=558). Patients w

    Patient flow. (a) One patient did not provide information on prior therapy so was not counted here, but was included in the overall efficacy and safety populations (total recruited: n=558). Patients who did not provide efficacy or safety data were excluded from the relevant study populations.

  • Image Result
    (a) Rates of minor hypoglycaemia at baseline, week 12 and week 26 (study end) stratified by pre-study treatment; (b) rates of nocturnal hypoglycaemia at baseline, week 12 and week 26 (study end) strat

    (a) Rates of minor hypoglycaemia at baseline, week 12 and week 26 (study end) stratified by pre-study treatment; (b) rates of nocturnal hypoglycaemia at baseline, week 12 and week 26 (study end) stratified by pre-study treatment. *p<0.05; **p<0.0001 vs. baseline.

  • Image Result
    HbA1c levels at baseline and after 12 and 26 weeks (final visit) of treatment with BIAsp 30 stratified by pre-study treatment. Error bars represent standard errors of the mean. *p<0.0001 vs. baseli

    HbA1c levels at baseline and after 12 and 26 weeks (final visit) of treatment with BIAsp 30 stratified by pre-study treatment. Error bars represent standard errors of the mean. *p<0.0001 vs. baseline. BIAsp, biphasic insulin aspart.

  • Image Result
    Fasting plasma glucose levels at baseline and after 12 and 26 weeks (final visit) of treatment with BIAsp 30 stratified by pre-study treatment. Error bars represent standard errors of the mean. *p<

    Fasting plasma glucose levels at baseline and after 12 and 26 weeks (final visit) of treatment with BIAsp 30 stratified by pre-study treatment. Error bars represent standard errors of the mean. *p<0.0001 vs. baseline. BIAsp, biphasic insulin aspart.

☆ Clinicaltrials.gov registration: NCT00696995.

PII: S0168-8227(11)00304-4

doi: 10.1016/j.diabres.2011.06.006

Diabetes Research and Clinical Practice
Volume 95, Issue 1 , Pages 10-18 , January 2012

Article Tools

* Image Usage & Resolution